Wed, October 26, 2011
Tue, October 25, 2011
Mon, October 24, 2011
[ Mon, Oct 24th 2011 ] - Market Wire
Cigna to Acquire HealthSpring
Sat, October 22, 2011
Fri, October 21, 2011
Thu, October 20, 2011
Wed, October 19, 2011
Tue, October 18, 2011
Mon, October 17, 2011
Sun, October 16, 2011
Sat, October 15, 2011
Fri, October 14, 2011
Thu, October 13, 2011
Wed, October 12, 2011
[ Wed, Oct 12th 2011 ] - Market Wire
Financial Statement 10/11
Tue, October 11, 2011

Marina Biotech, Inc. to Present at The 10th Annual BIO Investor Forum


//health-fitness.news-articles.net/content/2011/ .. esent-at-the-10th-annual-bio-investor-forum.html
Published in Health and Fitness on Wednesday, October 19th 2011 at 14:37 GMT by Market Wire   Print publication without navigation


October 19, 2011 17:30 ET

Marina Biotech, Inc. to Present at The 10th Annual BIO Investor Forum

BOTHELL, WA--(Marketwire - Oct 19, 2011) - Marina Biotech, Inc. (NASDAQ: [ MRNA ]), a leading oligonucleotide-based drug discovery and development company, announced today that it will present at The 10th Annual BIO Investor Forum on Wednesday, October 26, 2011, at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time) at the Palace Hotel in San Francisco. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at [ http://www.marinabio.com ]. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at [ http://www.marinabio.com ].



Publication Contributing Sources